# CRITICS-II (NCT02931890)

> Multicentric Randomised Trial for Resectable Gastric Cancer

No report yet. It can be ordered.

- Drugs tested: docetaxel plus oxaliplatin plus capecitabine; paclitaxel plus carboplatin
- Indication: resectable gastric cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02931890
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Gastric Cancer
- Interventions: Docetaxel; Oxaliplatin; Capecitabine; gastrectomy; radiotherapy of gastric cancer; Paclitaxel; Carboplatin
- Enrollment: 207
- Primary outcome: Event-Free survival

## Indexed commentary on CRITICS-II so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=critics-ii-nct02931890

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02931890", "email": "<work email>"}; the inbox owner confirms by the emailed link.